Phase II trial of a non‐platinum triplet for patients with advanced non‐small cell lung carcinoma (NSCLC) overexpressing ERCC1 messenger RNA

Phase II trial of a non‐platinum triplet for patients with advanced non‐small cell lung carcinoma (NSCLC) overexpressing ERCC1 messenger RNA

Background We prospectively evaluated the efficacy and toxicity of a non‐platinum triplet regimen for patients with advanced non‐small cell lung cancer (NSCLC) expected to be platinum‐resistant. Methods Patients were diagnosed with NSCLC using endobronchial ultrasonography with a guide sheath as a c...

Full description

Bibliographic Details
Main Authors: Shinnosuke Takemoto, Yoichi Nakamura, Hiroshi Gyoutoku, Hiroaki Senju, Daiki Ogawara, Takaya Ikeda, Hiroyuki Yamaguchi, Takeshi Kitazaki, Hirofumi Nakano, Katsumi Nakatomi, Shinya Tomari, Shuntaro Sato, Seiji Nagashima, Minoru Fukuda, Hiroshi Mukae
Format: Article
Language:English
Published: Wiley 2019-03-01
Series:Thoracic Cancer
Subjects:
Bevacizumab
excision repair cross‐complementation group 1
irinotecan
non‐small cell lung cancer
paclitaxel
Online Access:https://doi.org/10.1111/1759-7714.12958

Internet

https://doi.org/10.1111/1759-7714.12958

Similar Items